TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and...
Gilde Healthcare portfolio company Synox Therapeutics announces positive topline results from the Phase 3 TANGENT study
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and...
13 april 2026
Gilde Healthcare appoints Matthew Stork as CEO and Maarten Jaspers as Finance Director of its neuroimaging technology group
The neuroimaging group, consisting of Artinis and NIRx, leading in functional Near-Infrared Spectroscopy (fNIRS) solutions, has appointed Matthew Stork as Chief Executive Officer (CEO) and Maarten Jaspers as Finance Director....
5 februari 2026
Gilde Healthcare lanceert Climate Solutions fonds en haalt €250 mln op
Met commitments van internationale pensioenfondsen, banken, fund-of-funds, endowments en family offices realiseert Gilde Healthcare een eerste closing van €250 miljoen Uitbreiding naar Climate Solutions bouwt voort op Gilde Healthcare’s track-record...
18 februari 2026
Gilde Healthcare portfolio company Synox Therapeutics announces positive topline results from the Phase 3 TANGENT study
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and...
13 april 2026
Filter & zoek
Fonds strategie:
Loading...
Dit waren alle artikelen
737616b8b8